Daiwa Securities Group Inc. Sells 1,380 Shares of LivaNova PLC (NASDAQ:LIVN)

Daiwa Securities Group Inc. trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 7.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,285 shares of the company’s stock after selling 1,380 shares during the period. Daiwa Securities Group Inc.’s holdings in LivaNova were worth $1,349,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LIVN. Invesco Ltd. boosted its holdings in LivaNova by 376.8% during the second quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock valued at $165,437,000 after acquiring an additional 1,816,788 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in LivaNova by 18.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock valued at $172,349,000 after acquiring an additional 378,564 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in LivaNova by 1,661.4% during the second quarter. D. E. Shaw & Co. Inc. now owns 392,149 shares of the company’s stock valued at $28,219,000 after acquiring an additional 369,885 shares during the period. Primecap Management Co. CA boosted its holdings in LivaNova by 148.8% during the second quarter. Primecap Management Co. CA now owns 475,220 shares of the company’s stock valued at $34,197,000 after acquiring an additional 284,220 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its holdings in LivaNova by 2,237.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 271,100 shares of the company’s stock valued at $19,512,000 after acquiring an additional 259,500 shares during the period. Institutional investors own 89.74% of the company’s stock.

NASDAQ LIVN opened at $74.32 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.81 and a current ratio of 1.17. The firm has a 50-day simple moving average of $73.06 and a 200 day simple moving average of $74.38. LivaNova PLC has a twelve month low of $64.80 and a twelve month high of $126.99. The stock has a market cap of $3.55 billion, a PE ratio of 25.55, a PEG ratio of 3.34 and a beta of 0.53.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 30th. The company reported $0.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.09. LivaNova had a negative net margin of 20.35% and a positive return on equity of 9.44%. The business had revenue of $268.60 million during the quarter, compared to analysts’ expectations of $273.41 million. During the same quarter last year, the company earned $0.78 earnings per share. The firm’s revenue was down 1.3% on a year-over-year basis. Research analysts forecast that LivaNova PLC will post 2.69 earnings per share for the current fiscal year.

In related news, Director Daniel Jeffrey Moore sold 1,500 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $84.56, for a total value of $126,840.00. Also, CEO Damien Mcdonald sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $73.70, for a total transaction of $73,700.00. In the last quarter, insiders sold 6,000 shares of company stock valued at $471,735. 0.41% of the stock is owned by corporate insiders.

A number of equities research analysts have issued reports on LIVN shares. Needham & Company LLC decreased their price target on shares of LivaNova from $91.00 to $88.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. Berenberg Bank restated a “buy” rating and set a $114.00 price target on shares of LivaNova in a report on Monday, September 9th. Zacks Investment Research cut shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. ValuEngine upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, November 7th. Finally, BTIG Research restated a “hold” rating on shares of LivaNova in a report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $97.67.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Featured Story: What is Elliott Wave theory?

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.